Skip to main content
    PeptideAuthority
    Fact-checked by the Peptide Authority Editorial Board · Last reviewed:
    Share:X PostLinkedIn
    Hormonal & Endocrine•Updated 2026-02-01•5 min read

    What Is Sermorelin? Benefits, Research & Safety

    A truncated form of natural GHRH that was the first GHRH analogue approved for clinical use, used for GH deficiency diagnosis and treatment.

    Share:X PostLinkedIn
    Also known as:
    Sermorelin Acetate
    GRF 1-29
    Geref
    CLimited human evidenceUK: Unlicensed (UK)WADA: Prohibited in sport

    UK summary: Not currently licensed in the UK; the historical FDA-approved version (Geref) was withdrawn. GHRH analogue similar to CJC-1295 but shorter-acting. Prohibited at all times under WADA S2.

    Quick Facts

    Category
    Hormonal & Endocrine
    Half-Life
    Approximately 10-20 minutes
    UK Status
    Not licensed for human use. May be available through compounding pharmacies.
    EU Status
    Not widely approved; availability varies by country.

    Overview

    Sermorelin is a synthetic peptide consisting of the first 29 amino acids of the 44-amino acid human growth hormone-releasing hormone (GHRH 1-44). This shortened version retains full biological activity, as the first 29 amino acids contain the sequence necessary for receptor binding and activation. Unlike direct growth hormone administration, Sermorelin works by stimulating the pituitary gland to produce and release GH naturally. This approach maintains the body's normal feedback mechanisms and produces more physiological pulsatile GH release patterns. Sermorelin was approved by the FDA in 1997 for the diagnosis and treatment of growth hormone deficiency in children under the brand name Geref. However, it was later withdrawn from the market by the manufacturer for commercial reasons (not safety concerns) and is no longer commercially available in its original pharmaceutical form. The peptide remains available through compounding pharmacies in some countries and continues to be used in clinical practice for growth hormone optimisation, particularly in adults. It is also widely used in research settings.
    Evidence standards summary

    Sermorelin — evidence and risk at a glance

    Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.

    01Evidence snapshot

    CLimited human evidenceOverall grade against our evidence grading methodology.

    Not currently licensed in the UK; the historical FDA-approved version (Geref) was withdrawn. GHRH analogue similar to CJC-1295 but shorter-acting. Prohibited at all times under WADA S2.

    02Human evidence grade

    ETheoretical / insufficientStrength of evidence from published human trials.

    03Preclinical evidence grade

    BModerate human evidenceAnimal-model and in-vitro evidence quality.

    04Regulatory status

    • UK: Not licensed for human use. May be available through compounding pharmacies.
    • EU: Not widely approved; availability varies by country.
    • Notes: Sermorelin was FDA-approved but voluntarily withdrawn from the US market. It remains available through compounding pharmacies in some regions. It is prohibited in competitive sports.

    05Approved medical uses

    None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)

    06Unapproved / promotional claims

    • Reverses age-related growth-hormone decline in healthy adults.
    • Equivalent to HGH replacement without the cost or risks.
    • Improves body composition and skin quality in healthy ageing.
    • Safe long-term anti-ageing therapy.

    07Common internet claims

    • Marketed by private 'anti-ageing' clinics as a GH-restoring injection.
    • Sold via compounding pharmacies as a daily subcutaneous treatment.
    • Promoted as 'natural' GH stimulation compared with synthetic HGH.

    08Claim vs evidence

    ClaimEvidenceHuman evidence?Regulatory concernSafer wording
    “FDA-approved for adult GH deficiency”BYesLowSermorelin had FDA approval (Geref) for paediatric GH deficiency; the product was withdrawn from the US market. It is not currently a licensed UK medicine.
    “Safer anti-ageing than HGH”ENoHighComparative safety claims need comparative trials. Sermorelin is unlicensed in the UK; HGH is a controlled medicine.
    “Boosts natural GH for healthy adults”CLimitedModerateShort-term GH-response data exist; outcomes data in healthy adults are limited.

    09Safety uncertainty score

    Moderate

    Safety profile partly characterised; some signals from observational or preclinical data.

    10Known adverse signals

    • Injection-site reactions.
    • Flushing, headache, nausea.
    • Theoretical risks of chronic supraphysiological GH and IGF-1 elevation.
    • Unknown long-term cancer-risk implications.

    11Drug-interaction uncertainty

    High

    Interaction picture sparse; meaningful uncertainty when combined with other medicines.

    12Anti-doping status

    WADA: Prohibited in sportWADA strict-liability framing applies.

    13UK legal position

    UK: Unlicensed (UK)

    Not licensed for human use. May be available through compounding pharmacies.

    Read the full UK legal guide → Are peptides legal in the UK?

    14EU legal position

    Not widely approved; availability varies by country.

    15What this page cannot tell you

    • Whether a UK-purchased compounded Sermorelin contains the labelled peptide at the labelled concentration.
    • What chronic exposure does to insulin sensitivity, organ growth, or oncologic risk.
    • Whether it provides benefit in a healthy adult without diagnosed GH deficiency.
    • What the WADA in-competition exposure looks like — GH secretagogues are class-prohibited (S2).

    16Last reviewed

    Last reviewed:

    Next review due:

    Spotted an error or something out of date? Send a correction.

    17Citation quality score

    CLimited human evidenceQuality of the sources we cite, graded against the evidence grading methodology.

    18Research gaps

    • No registered Phase 3 trials in healthy adults for anti-ageing endpoints.
    • Long-term safety data largely absent.
    • Comparative head-to-head trials with HGH or other GH secretagogues are limited.
    • Outcome data (lean mass, bone density, quality of life) in healthy ageing is sparse.

    19Safer alternatives / established care pathways

    • GP and endocrinologist review if adult growth-hormone deficiency is clinically suspected, with ITT or GHRH-arginine testing.
    • Licensed recombinant HGH (Genotropin, Norditropin) under endocrinologist supervision where genuine deficiency is confirmed.
    • Resistance training and protein-adequate nutrition for body-composition goals in healthy ageing — the only evidence base.

    Related Safety Centre page → Clinic claim red flags

    20Doctor discussion prompts

    Questions to ask a qualified clinician

    These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

    • Is Sermorelin a licensed UK medicine?
    • If you suspect adult GH deficiency, what investigations would you do?
    • What licensed alternatives exist?
    • What is the WADA / UKAD position?

    Discovery & History

    Sermorelin was developed following the isolation and characterisation of natural human GHRH in 1982. When researchers sequenced the natural hormone, they discovered it was a 44-amino acid peptide. Subsequent studies revealed that the N-terminal portion (first 29 amino acids) was sufficient for full biological activity. This truncated peptide, designated GRF 1-29 or Sermorelin, was developed for therapeutic use because it was easier to synthesise than the full 44-amino acid peptide while retaining equivalent activity. Sermorelin acetate was approved by the FDA in 1997 under the brand name Geref for diagnosis and treatment of GH deficiency in children. It represented a novel approach—stimulating endogenous GH production rather than replacing GH directly. In 2008, the manufacturer (EMD Serono) voluntarily withdrew Geref from the market for business reasons rather than safety concerns. The company cited manufacturing challenges and commercial considerations. Despite the withdrawal of the branded product, Sermorelin has remained available through compounding pharmacies and continues to be used clinically, particularly in age-management medicine and for adult GH optimisation.

    Mechanism of Action

    Sermorelin works through the natural GHRH receptor pathway: **GHRH Receptor Binding** Sermorelin binds to GHRH receptors on somatotroph cells in the anterior pituitary gland. This triggers intracellular signalling cascades (primarily through cAMP) that stimulate growth hormone synthesis and release. **Pulsatile GH Release** Because Sermorelin works through natural feedback mechanisms, it produces pulsatile GH release similar to normal physiology. This contrasts with direct GH injection, which can suppress natural GH production. **Preserved Feedback Regulation** The pituitary's response to Sermorelin is regulated by normal feedback mechanisms. If GH or IGF-1 levels become too high, somatostatin release increases and suppresses further GH release. This makes overdose with dangerous GH levels unlikely. **Synergy with GHRPs** Like other GHRH analogues, Sermorelin can be combined with GHRPs (which work through the ghrelin receptor) for synergistic effects on GH release. **Stimulation of Pituitary Function** Some research suggests that long-term Sermorelin use may help maintain or even improve pituitary function, potentially "rejuvenating" the growth hormone axis.

    Researched Benefits

    Based on preclinical and clinical research findings:

    • 1
      Physiological stimulation of growth hormone release
    • 2
      Elevated IGF-1 levels through natural mechanisms
    • 3
      Maintenance of normal GH pulsatility and feedback
    • 4
      Potential improvements in body composition
    • 5
      Possible enhancement of sleep quality (GH release during sleep)
    • 6
      Lower risk of excessive GH levels compared to direct GH injection
    • 7
      May support pituitary function long-term

    Claim vs Evidence

    How popular claims about Sermorelin stack up against the current research, graded using our public evidence grading methodology.

    ClaimEvidenceHuman evidence?Regulatory concernSafer wording
    “FDA-approved for adult GH deficiency”BYesLowSermorelin had FDA approval (Geref) for paediatric GH deficiency; the product was withdrawn from the US market. It is not currently a licensed UK medicine.
    “Safer anti-ageing than HGH”ENoHighComparative safety claims need comparative trials. Sermorelin is unlicensed in the UK; HGH is a controlled medicine.
    “Boosts natural GH for healthy adults”CLimitedModerateShort-term GH-response data exist; outcomes data in healthy adults are limited.

    Theoretical Dosing & Protocols

    ⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.
    Theoretical Dosage200-300 mcg per dose (based on historical clinical use)
    FrequencyOnce daily, typically at bedtime
    DurationOngoing; often used long-term for GH optimisation
    NotesSermorelin was previously an approved medication. It is still available through compounding pharmacies in some regions. Use should be under medical supervision with appropriate monitoring of GH and IGF-1 levels.

    Administration Routes

    Routes studied in research settings (educational only):

    • Subcutaneous injection (most common)
    Half-LifeStability
    Approximately 10-20 minutesLyophilised powder stable when properly stored; reconstituted solution should be refrigerated

    Safety Profile & Known Risks

    Commonly Reported Side Effects

    • Injection site reactions (redness, swelling, pain)
    • Flushing immediately after injection
    • Headache
    • Dizziness

    Rare Risks & Concerns

    • Antibody formation (reduced efficacy over time)
    • Effects on glucose metabolism
    • Theoretical concerns shared with all GH-releasing agents

    Contraindications

    • Active malignancy
    • Pregnancy and breastfeeding
    • Hypersensitivity to Sermorelin or GHRH
    • Certain brain lesions or tumours affecting the pituitary

    UK & EU Regulatory Context

    🇬🇧 United Kingdom

    Not licensed for human use. May be available through compounding pharmacies.

    🇪🇺 European Union

    Not widely approved; availability varies by country.

    Sermorelin was FDA-approved but voluntarily withdrawn from the US market. It remains available through compounding pharmacies in some regions. It is prohibited in competitive sports.

    Clinical Studies Summary

    A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.

    In conclusion, peptides represent a new phase in performance enhancement but remain experimental substances with poorly defined long-term risks. Until longitudinal data clarify their safety and prevalence, peptide use in both competitive and recreational settings should be considered high-risk and ethically problematic.

    J Sports Med Phys Fitness. 2026View on PubMed

    The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.

    We summarise structural characteristics, pharmacologic effects, and commonly reported dosing patterns, and we synthesise clinically relevant adverse effects with particular attention to hormonal imbalance, endocrine-metabolic risk, and biologically plausible but unproven mitogenic concerns.

    Front Endocrinol (Lausanne). 2026View on PubMed

    PEGylation of growth hormone-releasing hormone (GRF) analogues.

    The effect of PEG molecular weight, number of PEG chains bound and position of PEGylation site on GRF activity were investigated. Mono-PEGylated isomers with a PEG5000 polymer chain linked to Lys 12 or Lys 21 residues, showed high biological activity in vitro, which is similar to that of hGRF1-29, and a higher pharmacodynamic response as compared to unmodified GRF molecule.

    Adv Drug Deliv Rev. 2003View on PubMed

    Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.

    5-0. 75 ng/mL) demonstrated sufficient sensitivity for effective detection and confirmation analysis of the target peptides in urine.

    J Pharm Biomed Anal. 2026View on PubMed

    Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples.

    Nearly all requirements of the recent technical documents from the World Anti-Doping Agency (WADA) considering their minimum required performance levels (MRPL) are fulfilled, and the method was validated for its utilisation as initial testing procedure in doping controls.

    J Mass Spectrom. 2024View on PubMed

    Online large volume sample staking preconcentration and separation of enantiomeric GHRH analogs by capillary electrophoresis.

    An optimized C18 SPE was used for that purpose in order to provide low sample conductivity (<130 µS/cm) and preserve the efficiency of LVSS preconcentration. SEF of 640 was obtained with desalted urine spiked with sermorelin by comparison to the CZE (without preconcentration) method.

    Electrophoresis. 2023View on PubMed

    Looking for Sermorelin?

    Source research-grade Sermorelin from a trusted UK supplier — third-party tested with certificate of analysis.

    View at Supplier

    Frequently Asked Questions

    Questions to ask a qualified clinician about Sermorelin

    These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

    • Is Sermorelin a licensed UK medicine?
    • If you suspect adult GH deficiency, what investigations would you do?
    • What licensed alternatives exist?
    • What is the WADA / UKAD position?

    UK regulatory & safety context

    Are peptides legal in the UK?

    UK legal reference

    Clinic claim red flags

    Safety Centre guide

    Related Research Guides

    Peptides for Muscle Growth

    Read guide

    Peptides for Anti-Ageing

    Read guide

    Peptides for Sleep Optimization

    Read guide

    Peptide Comparisons

    Tesamorelin vs Sermorelin

    Compare peptides

    Sermorelin vs CJC-1295

    Compare peptides

    GHRP-2 vs GHRP-6

    Compare peptides

    Hexarelin vs Ipamorelin

    Compare peptides

    Related Peptides

    CJC-1295

    A synthetic growth hormone-releasing hormone analogue designed for extended half-life and sustained growth hormone secretion.

    Learn more

    Ipamorelin

    A selective growth hormone-releasing peptide known for its favourable side effect profile, stimulating GH release without significantly affecting cortisol or prolactin.

    Learn more

    GHRP-2

    A potent growth hormone-releasing peptide that stimulates GH secretion through the ghrelin receptor, with additional effects on appetite and cortisol.

    Learn more

    Tesamorelin

    An FDA-approved growth hormone releasing hormone analogue used to reduce excess abdominal fat in HIV patients with lipodystrophy.

    Learn more

    Explore More Peptides

    Browse our comprehensive database of research-backed peptide profiles.